semgine GmbH - Product release of the semgine sciPlorer® 1.3

Berlin software enterprise semgine GmbH has completed the new release of its semgine sciPlorer®. semgine sciPlorer® is the first product based on the semgine® semantic search technology and the first semantic information retrieval assistant specially developed for researchers working in the field of drugs discovery and biomedical science.

Version 1.3 of the semgine sciPlorer® enables scientists to have terms explained to them simply using brief, concise collections of facts. At the same time, the results filtering has been fundamentally expanded, so more and better results can now be achieved.

"The reports now available, with their brief, clear facts, allow for very fast and effortless information acquisition and are a clear unique selling proposition for the semgine sciPlorer®" explains Dr Martin C. Hirsch, CEO of semgine GmbH. "With the extraction of facts from the Internet, we are consistently expanding the semgine sciPlorer®, developing it into a semantic search engine for the biomedical sciences. We’ve brought Web 3.0 a step closer for the biomedical sciences."

The semgine sciPlorer® is based on a completely new approach, which applies the principles of cognitive neuroscience to information processing. While conventional search engines create a normal word-based, full-text index of documents, semgine® builds up a semantic index, enabling users to accurately pinpoint individual facts in documents.

"We've really 'hit a nerve' in the community with the semgine sciPlorer®" notes Dr Thomas Meyer, Sales Manager Life Sciences at semgine GmbH. "A test customer summed it up aptly: With the semgine sciPlorer® you've developed an excellent information retrieval solution with a technically perfected refinement strategy."

About semgine GmbH
semgine GmbH (www.semgine.com) develops software frameworks for building semantic knowledge assistants for the Web 3.0. Its unique approach, utilising Brainlike Information Management, is derived from current insights into cognitive neurosciences, forming the basis for cutting-edge software technology designed to retrieve complex information relationships quickly and accurately.

The company was founded in 1994 by Dr Martin C. Hirsch, neurobiologist and grandson of physicist and Nobel Laureate Werner Heisenberg. semgine GmbH focuses on the life sciences sector and its customers include Altana Pharma AG, BBraun AG, Honda Research Institute Europe and Sanofi-Aventis Deutschland GmbH. The core technology is funded by the German Ministry of Education and Research and, within the BioSim project, by the 6th Framework Programme of the European Commission.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...